Marina Deodato

6PUBLICATIONS
39CO-AUTHORS
Immunogenetics (incl. genetic immunology)Predictive and prognostic markersNutrigenomics and personalised nutritionCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 29, 2026
Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

Luca Arcaini, Michele Merli, Sara Rattotti

|Feb 10, 2026
Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study.

Lucia Farina, Alessandro Noto, Antonella Aiello

|Jun 27, 2025
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing-Neel Syndrome.

Anna Maria Frustaci, Arianna Zappaterra, Gloria Turri

|Feb 12, 2024
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.

Francesco Autore, Andrea Visentin, Marina Deodato

|Mar 28, 2022
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.

Marina Deodato, Anna Maria Frustaci, Paolo Sportoletti

|Feb 16, 2022
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.

Stefano Molica, Diana Giannarelli, Andrea Visentin

Pageof 1

Frequent Collaborators

2 joint publications

Anna Maria Frustaci

2 joint publications

Luca Laurenti

2 joint publications

Riccardo Moia

1 joint publications

Stefano Molica